Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer
Randomized Phase II Trial of Gemcitabine and Imatinib Mesylate Versus Gemcitabine Alone in Patients With Previously Treated Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated:  10/23/2017
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer
Randomized Phase II Trial of Gemcitabine and Imatinib Mesylate Versus Gemcitabine Alone in Patients With Previously Treated Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 10/23/2017
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer
Randomized Phase II Trial of Gemcitabine and Imatinib Mesylate Versus Gemcitabine Alone in Patients With Previously Treated Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated:  10/23/2017
Mountainside Hospital
mi
from
Montclair, NJ
Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer
Randomized Phase II Trial of Gemcitabine and Imatinib Mesylate Versus Gemcitabine Alone in Patients With Previously Treated Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 10/23/2017
Mountainside Hospital
mi
from
Montclair, NJ
Click here to add this to my saved trials
Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer
Randomized Phase II Trial of Gemcitabine and Imatinib Mesylate Versus Gemcitabine Alone in Patients With Previously Treated Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated:  10/23/2017
Saint Peter's University Hospital
mi
from
New Brunswick, NJ
Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer
Randomized Phase II Trial of Gemcitabine and Imatinib Mesylate Versus Gemcitabine Alone in Patients With Previously Treated Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 10/23/2017
Saint Peter's University Hospital
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer
Randomized Phase II Trial of Gemcitabine and Imatinib Mesylate Versus Gemcitabine Alone in Patients With Previously Treated Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated:  10/23/2017
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer
Randomized Phase II Trial of Gemcitabine and Imatinib Mesylate Versus Gemcitabine Alone in Patients With Previously Treated Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 10/23/2017
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer
Randomized Phase II Trial of Gemcitabine and Imatinib Mesylate Versus Gemcitabine Alone in Patients With Previously Treated Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated:  10/23/2017
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer
Randomized Phase II Trial of Gemcitabine and Imatinib Mesylate Versus Gemcitabine Alone in Patients With Previously Treated Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 10/23/2017
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Click here to add this to my saved trials
Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer
Randomized Phase II Trial of Gemcitabine and Imatinib Mesylate Versus Gemcitabine Alone in Patients With Previously Treated Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated:  10/23/2017
Rutgers Cancer Institute of New Jersey at Hamilton
mi
from
Hamilton, NJ
Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer
Randomized Phase II Trial of Gemcitabine and Imatinib Mesylate Versus Gemcitabine Alone in Patients With Previously Treated Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 10/23/2017
Rutgers Cancer Institute of New Jersey at Hamilton
mi
from
Hamilton, NJ
Click here to add this to my saved trials
Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer
Randomized Phase II Trial of Gemcitabine and Imatinib Mesylate Versus Gemcitabine Alone in Patients With Previously Treated Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated:  10/23/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer
Randomized Phase II Trial of Gemcitabine and Imatinib Mesylate Versus Gemcitabine Alone in Patients With Previously Treated Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 10/23/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer
Randomized Phase II Trial of Gemcitabine and Imatinib Mesylate Versus Gemcitabine Alone in Patients With Previously Treated Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated:  10/23/2017
NJ Medical School
mi
from
Newark, NJ
Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer
Randomized Phase II Trial of Gemcitabine and Imatinib Mesylate Versus Gemcitabine Alone in Patients With Previously Treated Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 10/23/2017
NJ Medical School
mi
from
Newark, NJ
Click here to add this to my saved trials
Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer
Randomized Phase II Trial of Gemcitabine and Imatinib Mesylate Versus Gemcitabine Alone in Patients With Previously Treated Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated:  10/23/2017
Jersey Shore Cancer Center at Jersey Shore University Medical Center
mi
from
Neptune City, NJ
Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer
Randomized Phase II Trial of Gemcitabine and Imatinib Mesylate Versus Gemcitabine Alone in Patients With Previously Treated Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 10/23/2017
Jersey Shore Cancer Center at Jersey Shore University Medical Center
mi
from
Neptune City, NJ
Click here to add this to my saved trials
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated:  10/24/2017
University of Chicago
mi
from
Chicago, IL
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated: 10/24/2017
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated:  10/24/2017
Dana Farber Cancer Center Institute
mi
from
Boston, MA
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated: 10/24/2017
Dana Farber Cancer Center Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated:  10/24/2017
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated: 10/24/2017
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated:  10/24/2017
University of Alabama at Birmingham (UAB)
mi
from
Birmingham, AL
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated: 10/24/2017
University of Alabama at Birmingham (UAB)
mi
from
Birmingham, AL
Click here to add this to my saved trials
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated:  10/24/2017
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated: 10/24/2017
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated:  10/24/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated: 10/24/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated:  10/24/2017
Univ of North Carolina
mi
from
Chapel Hill, NC
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated: 10/24/2017
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated:  10/24/2017
Vanderbilt University
mi
from
Nashville, TN
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated: 10/24/2017
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated:  10/24/2017
Baylor University
mi
from
Houston, TX
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated: 10/24/2017
Baylor University
mi
from
Houston, TX
Click here to add this to my saved trials
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated:  10/24/2017
Georgetown University Medical Center
mi
from
Washington, D.C.,
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated: 10/24/2017
Georgetown University Medical Center
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Limonene Study in Women With Breast Cancer
Clinical Study of Limonene in Women With a Recent Diagnosis of Early Stage Breast Cancer Electing to Undergo Excision Surgery
Status: Enrolling
Updated:  10/25/2017
Arizona Cancer Center
mi
from
Tucson, AZ
Limonene Study in Women With Breast Cancer
Clinical Study of Limonene in Women With a Recent Diagnosis of Early Stage Breast Cancer Electing to Undergo Excision Surgery
Status: Enrolling
Updated: 10/25/2017
Arizona Cancer Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Brief Behavioral Therapy in Improving Sleep Disorders in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
Feasibility, Acceptability and Mechanisms of Brief Behavioral Therapy (BBT) for Sleep Problems During Chemotherapy: A Phase II Randomized Controlled Trial
Status: Enrolling
Updated:  10/25/2017
Stanford Univ Med Ctr
mi
from
Stanford, CA
Brief Behavioral Therapy in Improving Sleep Disorders in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
Feasibility, Acceptability and Mechanisms of Brief Behavioral Therapy (BBT) for Sleep Problems During Chemotherapy: A Phase II Randomized Controlled Trial
Status: Enrolling
Updated: 10/25/2017
Stanford Univ Med Ctr
mi
from
Stanford, CA
Click here to add this to my saved trials
Brief Behavioral Therapy in Improving Sleep Disorders in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
Feasibility, Acceptability and Mechanisms of Brief Behavioral Therapy (BBT) for Sleep Problems During Chemotherapy: A Phase II Randomized Controlled Trial
Status: Enrolling
Updated:  10/25/2017
Heartland NCORP
mi
from
Decatur, IL
Brief Behavioral Therapy in Improving Sleep Disorders in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
Feasibility, Acceptability and Mechanisms of Brief Behavioral Therapy (BBT) for Sleep Problems During Chemotherapy: A Phase II Randomized Controlled Trial
Status: Enrolling
Updated: 10/25/2017
Heartland NCORP
mi
from
Decatur, IL
Click here to add this to my saved trials
Brief Behavioral Therapy in Improving Sleep Disorders in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
Feasibility, Acceptability and Mechanisms of Brief Behavioral Therapy (BBT) for Sleep Problems During Chemotherapy: A Phase II Randomized Controlled Trial
Status: Enrolling
Updated:  10/25/2017
Wichita NCORP
mi
from
Wichita, KA
Brief Behavioral Therapy in Improving Sleep Disorders in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
Feasibility, Acceptability and Mechanisms of Brief Behavioral Therapy (BBT) for Sleep Problems During Chemotherapy: A Phase II Randomized Controlled Trial
Status: Enrolling
Updated: 10/25/2017
Wichita NCORP
mi
from
Wichita, KA
Click here to add this to my saved trials
Brief Behavioral Therapy in Improving Sleep Disorders in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
Feasibility, Acceptability and Mechanisms of Brief Behavioral Therapy (BBT) for Sleep Problems During Chemotherapy: A Phase II Randomized Controlled Trial
Status: Enrolling
Updated:  10/25/2017
Metro Minnesota NCORP
mi
from
Minneapolis, MN
Brief Behavioral Therapy in Improving Sleep Disorders in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
Feasibility, Acceptability and Mechanisms of Brief Behavioral Therapy (BBT) for Sleep Problems During Chemotherapy: A Phase II Randomized Controlled Trial
Status: Enrolling
Updated: 10/25/2017
Metro Minnesota NCORP
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Brief Behavioral Therapy in Improving Sleep Disorders in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
Feasibility, Acceptability and Mechanisms of Brief Behavioral Therapy (BBT) for Sleep Problems During Chemotherapy: A Phase II Randomized Controlled Trial
Status: Enrolling
Updated:  10/25/2017
University of Rochester
mi
from
Rochester, NY
Brief Behavioral Therapy in Improving Sleep Disorders in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
Feasibility, Acceptability and Mechanisms of Brief Behavioral Therapy (BBT) for Sleep Problems During Chemotherapy: A Phase II Randomized Controlled Trial
Status: Enrolling
Updated: 10/25/2017
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
Brief Behavioral Therapy in Improving Sleep Disorders in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
Feasibility, Acceptability and Mechanisms of Brief Behavioral Therapy (BBT) for Sleep Problems During Chemotherapy: A Phase II Randomized Controlled Trial
Status: Enrolling
Updated:  10/25/2017
Southeast Clinical Oncology Research Program
mi
from
Winston-Salem, NC
Brief Behavioral Therapy in Improving Sleep Disorders in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
Feasibility, Acceptability and Mechanisms of Brief Behavioral Therapy (BBT) for Sleep Problems During Chemotherapy: A Phase II Randomized Controlled Trial
Status: Enrolling
Updated: 10/25/2017
Southeast Clinical Oncology Research Program
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Development of Vitamin D as a Therapy for Breast Cancer - Phase 2
Development of Vitamin D as a Therapy for Breast Cancer - Phase 2
Status: Enrolling
Updated:  10/26/2017
Stanford University School of Medicine
mi
from
Stanford, CA
Development of Vitamin D as a Therapy for Breast Cancer - Phase 2
Development of Vitamin D as a Therapy for Breast Cancer - Phase 2
Status: Enrolling
Updated: 10/26/2017
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer
Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer
Status: Enrolling
Updated:  10/26/2017
Indiana University Melvin and Bren Simon Cancer Center (IUSCC)
mi
from
Indianapolis, IN
Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer
Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer
Status: Enrolling
Updated: 10/26/2017
Indiana University Melvin and Bren Simon Cancer Center (IUSCC)
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer
Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer
Status: Enrolling
Updated:  10/26/2017
Syndney & Lois Eskenazi Health Center
mi
from
Indianapolis, IN
Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer
Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer
Status: Enrolling
Updated: 10/26/2017
Syndney & Lois Eskenazi Health Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen
A Phase II Study of GW572016 and Tamoxifen in Patients With Metastatic Breast Cancer Resistant to Single-Agent Tamoxifen
Status: Enrolling
Updated:  10/27/2017
Harper University Hospital - DMC
mi
from
Detroit, MI
Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen
A Phase II Study of GW572016 and Tamoxifen in Patients With Metastatic Breast Cancer Resistant to Single-Agent Tamoxifen
Status: Enrolling
Updated: 10/27/2017
Harper University Hospital - DMC
mi
from
Detroit, MI
Click here to add this to my saved trials
Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen
A Phase II Study of GW572016 and Tamoxifen in Patients With Metastatic Breast Cancer Resistant to Single-Agent Tamoxifen
Status: Enrolling
Updated:  10/27/2017
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen
A Phase II Study of GW572016 and Tamoxifen in Patients With Metastatic Breast Cancer Resistant to Single-Agent Tamoxifen
Status: Enrolling
Updated: 10/27/2017
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of LY2523355 in Participants With Breast Cancer
A Randomized Phase 2 Study of LY2523355 Versus Ixabepilone in Patients With Metastatic or Locally Recurrent Breast Cancer Who Have Received Prior Taxane Therapy
Status: Enrolling
Updated:  10/28/2017
Clinical Research Facility
mi
from
Bethesda, MD
A Study of LY2523355 in Participants With Breast Cancer
A Randomized Phase 2 Study of LY2523355 Versus Ixabepilone in Patients With Metastatic or Locally Recurrent Breast Cancer Who Have Received Prior Taxane Therapy
Status: Enrolling
Updated: 10/28/2017
Clinical Research Facility
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Study of LY2523355 in Participants With Breast Cancer
A Randomized Phase 2 Study of LY2523355 Versus Ixabepilone in Patients With Metastatic or Locally Recurrent Breast Cancer Who Have Received Prior Taxane Therapy
Status: Enrolling
Updated:  10/28/2017
Clinical Research Facility
mi
from
Fort Myers, FL
A Study of LY2523355 in Participants With Breast Cancer
A Randomized Phase 2 Study of LY2523355 Versus Ixabepilone in Patients With Metastatic or Locally Recurrent Breast Cancer Who Have Received Prior Taxane Therapy
Status: Enrolling
Updated: 10/28/2017
Clinical Research Facility
mi
from
Fort Myers, FL
Click here to add this to my saved trials
A Study of LY2523355 in Participants With Breast Cancer
A Randomized Phase 2 Study of LY2523355 Versus Ixabepilone in Patients With Metastatic or Locally Recurrent Breast Cancer Who Have Received Prior Taxane Therapy
Status: Enrolling
Updated:  10/28/2017
Clinical Research Facility
mi
from
Pensacola, FL
A Study of LY2523355 in Participants With Breast Cancer
A Randomized Phase 2 Study of LY2523355 Versus Ixabepilone in Patients With Metastatic or Locally Recurrent Breast Cancer Who Have Received Prior Taxane Therapy
Status: Enrolling
Updated: 10/28/2017
Clinical Research Facility
mi
from
Pensacola, FL
Click here to add this to my saved trials
A Study of LY2523355 in Participants With Breast Cancer
A Randomized Phase 2 Study of LY2523355 Versus Ixabepilone in Patients With Metastatic or Locally Recurrent Breast Cancer Who Have Received Prior Taxane Therapy
Status: Enrolling
Updated:  10/28/2017
Clinical Research Facility
mi
from
Gainesville, GA
A Study of LY2523355 in Participants With Breast Cancer
A Randomized Phase 2 Study of LY2523355 Versus Ixabepilone in Patients With Metastatic or Locally Recurrent Breast Cancer Who Have Received Prior Taxane Therapy
Status: Enrolling
Updated: 10/28/2017
Clinical Research Facility
mi
from
Gainesville, GA
Click here to add this to my saved trials
A Study of LY2523355 in Participants With Breast Cancer
A Randomized Phase 2 Study of LY2523355 Versus Ixabepilone in Patients With Metastatic or Locally Recurrent Breast Cancer Who Have Received Prior Taxane Therapy
Status: Enrolling
Updated:  10/28/2017
Clinical Research Facility
mi
from
Cincinnati, OH
A Study of LY2523355 in Participants With Breast Cancer
A Randomized Phase 2 Study of LY2523355 Versus Ixabepilone in Patients With Metastatic or Locally Recurrent Breast Cancer Who Have Received Prior Taxane Therapy
Status: Enrolling
Updated: 10/28/2017
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of LY2523355 in Participants With Breast Cancer
A Randomized Phase 2 Study of LY2523355 Versus Ixabepilone in Patients With Metastatic or Locally Recurrent Breast Cancer Who Have Received Prior Taxane Therapy
Status: Enrolling
Updated:  10/28/2017
Clinical Research Facility
mi
from
Toledo, OH
A Study of LY2523355 in Participants With Breast Cancer
A Randomized Phase 2 Study of LY2523355 Versus Ixabepilone in Patients With Metastatic or Locally Recurrent Breast Cancer Who Have Received Prior Taxane Therapy
Status: Enrolling
Updated: 10/28/2017
Clinical Research Facility
mi
from
Toledo, OH
Click here to add this to my saved trials
A Study of LY2523355 in Participants With Breast Cancer
A Randomized Phase 2 Study of LY2523355 Versus Ixabepilone in Patients With Metastatic or Locally Recurrent Breast Cancer Who Have Received Prior Taxane Therapy
Status: Enrolling
Updated:  10/28/2017
Clinical Research Facility
mi
from
Columbia, SC
A Study of LY2523355 in Participants With Breast Cancer
A Randomized Phase 2 Study of LY2523355 Versus Ixabepilone in Patients With Metastatic or Locally Recurrent Breast Cancer Who Have Received Prior Taxane Therapy
Status: Enrolling
Updated: 10/28/2017
Clinical Research Facility
mi
from
Columbia, SC
Click here to add this to my saved trials
A Study of LY2523355 in Participants With Breast Cancer
A Randomized Phase 2 Study of LY2523355 Versus Ixabepilone in Patients With Metastatic or Locally Recurrent Breast Cancer Who Have Received Prior Taxane Therapy
Status: Enrolling
Updated:  10/28/2017
Clinical Research Facility
mi
from
Spartanburg, SC
A Study of LY2523355 in Participants With Breast Cancer
A Randomized Phase 2 Study of LY2523355 Versus Ixabepilone in Patients With Metastatic or Locally Recurrent Breast Cancer Who Have Received Prior Taxane Therapy
Status: Enrolling
Updated: 10/28/2017
Clinical Research Facility
mi
from
Spartanburg, SC
Click here to add this to my saved trials
A Study of LY2523355 in Participants With Breast Cancer
A Randomized Phase 2 Study of LY2523355 Versus Ixabepilone in Patients With Metastatic or Locally Recurrent Breast Cancer Who Have Received Prior Taxane Therapy
Status: Enrolling
Updated:  10/28/2017
Clinical Research Facility
mi
from
Chattanooga, TN
A Study of LY2523355 in Participants With Breast Cancer
A Randomized Phase 2 Study of LY2523355 Versus Ixabepilone in Patients With Metastatic or Locally Recurrent Breast Cancer Who Have Received Prior Taxane Therapy
Status: Enrolling
Updated: 10/28/2017
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
A Study of LY2523355 in Participants With Breast Cancer
A Randomized Phase 2 Study of LY2523355 Versus Ixabepilone in Patients With Metastatic or Locally Recurrent Breast Cancer Who Have Received Prior Taxane Therapy
Status: Enrolling
Updated:  10/28/2017
Clinical Research Facility
mi
from
Nashville, TN
A Study of LY2523355 in Participants With Breast Cancer
A Randomized Phase 2 Study of LY2523355 Versus Ixabepilone in Patients With Metastatic or Locally Recurrent Breast Cancer Who Have Received Prior Taxane Therapy
Status: Enrolling
Updated: 10/28/2017
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of LY2523355 in Participants With Breast Cancer
A Randomized Phase 2 Study of LY2523355 Versus Ixabepilone in Patients With Metastatic or Locally Recurrent Breast Cancer Who Have Received Prior Taxane Therapy
Status: Enrolling
Updated:  10/28/2017
Clinical Research Facility
mi
from
Fort Worth, TX
A Study of LY2523355 in Participants With Breast Cancer
A Randomized Phase 2 Study of LY2523355 Versus Ixabepilone in Patients With Metastatic or Locally Recurrent Breast Cancer Who Have Received Prior Taxane Therapy
Status: Enrolling
Updated: 10/28/2017
Clinical Research Facility
mi
from
Fort Worth, TX
Click here to add this to my saved trials
A Study of LY2523355 in Participants With Breast Cancer
A Randomized Phase 2 Study of LY2523355 Versus Ixabepilone in Patients With Metastatic or Locally Recurrent Breast Cancer Who Have Received Prior Taxane Therapy
Status: Enrolling
Updated:  10/28/2017
Clinical Research Facility
mi
from
Richmond, VA
A Study of LY2523355 in Participants With Breast Cancer
A Randomized Phase 2 Study of LY2523355 Versus Ixabepilone in Patients With Metastatic or Locally Recurrent Breast Cancer Who Have Received Prior Taxane Therapy
Status: Enrolling
Updated: 10/28/2017
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
Breast Cancer Rehabilitation Program in Improving Quality of Life in Breast Cancer Survivors
A Pilot Study to Evaluate the Feasibility of a Breast Cancer Rehabilitation Program in Survivors of Breast Cancer
Status: Enrolling
Updated:  10/30/2017
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Breast Cancer Rehabilitation Program in Improving Quality of Life in Breast Cancer Survivors
A Pilot Study to Evaluate the Feasibility of a Breast Cancer Rehabilitation Program in Survivors of Breast Cancer
Status: Enrolling
Updated: 10/30/2017
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Home-based Compression Therapy for Arm and Truncal Lymphedema in Breast Cancer
Home-based Compression Therapy for Arm and Truncal Lymphedema in Breast Cancer
Status: Enrolling
Updated:  11/1/2017
Vanderbilt Univeristy
mi
from
Nashville, TN
Home-based Compression Therapy for Arm and Truncal Lymphedema in Breast Cancer
Home-based Compression Therapy for Arm and Truncal Lymphedema in Breast Cancer
Status: Enrolling
Updated: 11/1/2017
Vanderbilt Univeristy
mi
from
Nashville, TN
Click here to add this to my saved trials
Acupuncture in Treating Nerve Pain in Patients With Stage I, Stage II, or Stage III Breast Cancer Who Are Receiving Paclitaxel
A Pilot Study Investigating the Feasibility of Using Acupuncture for the Treatment of Taxane-Induced Peripheral Neuropathy
Status: Enrolling
Updated:  11/2/2017
City of Hope Medical Group Inc
mi
from
Pasadena, CA
Acupuncture in Treating Nerve Pain in Patients With Stage I, Stage II, or Stage III Breast Cancer Who Are Receiving Paclitaxel
A Pilot Study Investigating the Feasibility of Using Acupuncture for the Treatment of Taxane-Induced Peripheral Neuropathy
Status: Enrolling
Updated: 11/2/2017
City of Hope Medical Group Inc
mi
from
Pasadena, CA
Click here to add this to my saved trials
Acupuncture in Treating Nerve Pain in Patients With Stage I, Stage II, or Stage III Breast Cancer Who Are Receiving Paclitaxel
A Pilot Study Investigating the Feasibility of Using Acupuncture for the Treatment of Taxane-Induced Peripheral Neuropathy
Status: Enrolling
Updated:  11/2/2017
City of Hope
mi
from
Duarte, CA
Acupuncture in Treating Nerve Pain in Patients With Stage I, Stage II, or Stage III Breast Cancer Who Are Receiving Paclitaxel
A Pilot Study Investigating the Feasibility of Using Acupuncture for the Treatment of Taxane-Induced Peripheral Neuropathy
Status: Enrolling
Updated: 11/2/2017
City of Hope
mi
from
Duarte, CA
Click here to add this to my saved trials
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)
A Randomized, 3 Arm, Multicenter, Phase III Study to Evaluate the Efficacy and the Safety of T-DM1 Combined With Pertuzumab or T-DM1 Combined With Pertuzumab-Placebo (Blinded for Pertuzumab), Versus the Combination of Trastuzumab Plus Taxane, as First Line Treatment in HER2 Positive Progressive or Recurrent Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated:  11/3/2017
Arizona Oncology
mi
from
Tucson, AZ
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)
A Randomized, 3 Arm, Multicenter, Phase III Study to Evaluate the Efficacy and the Safety of T-DM1 Combined With Pertuzumab or T-DM1 Combined With Pertuzumab-Placebo (Blinded for Pertuzumab), Versus the Combination of Trastuzumab Plus Taxane, as First Line Treatment in HER2 Positive Progressive or Recurrent Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 11/3/2017
Arizona Oncology
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)
A Randomized, 3 Arm, Multicenter, Phase III Study to Evaluate the Efficacy and the Safety of T-DM1 Combined With Pertuzumab or T-DM1 Combined With Pertuzumab-Placebo (Blinded for Pertuzumab), Versus the Combination of Trastuzumab Plus Taxane, as First Line Treatment in HER2 Positive Progressive or Recurrent Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated:  11/3/2017
Uni of Arkansas For Medical Sciences; Arkansas Cancer Research Center
mi
from
Little Rock, AR
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)
A Randomized, 3 Arm, Multicenter, Phase III Study to Evaluate the Efficacy and the Safety of T-DM1 Combined With Pertuzumab or T-DM1 Combined With Pertuzumab-Placebo (Blinded for Pertuzumab), Versus the Combination of Trastuzumab Plus Taxane, as First Line Treatment in HER2 Positive Progressive or Recurrent Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 11/3/2017
Uni of Arkansas For Medical Sciences; Arkansas Cancer Research Center
mi
from
Little Rock, AR
Click here to add this to my saved trials
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)
A Randomized, 3 Arm, Multicenter, Phase III Study to Evaluate the Efficacy and the Safety of T-DM1 Combined With Pertuzumab or T-DM1 Combined With Pertuzumab-Placebo (Blinded for Pertuzumab), Versus the Combination of Trastuzumab Plus Taxane, as First Line Treatment in HER2 Positive Progressive or Recurrent Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated:  11/3/2017
Little Rock Hematology Oncology Associates, PA
mi
from
Little Rock, AR
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)
A Randomized, 3 Arm, Multicenter, Phase III Study to Evaluate the Efficacy and the Safety of T-DM1 Combined With Pertuzumab or T-DM1 Combined With Pertuzumab-Placebo (Blinded for Pertuzumab), Versus the Combination of Trastuzumab Plus Taxane, as First Line Treatment in HER2 Positive Progressive or Recurrent Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 11/3/2017
Little Rock Hematology Oncology Associates, PA
mi
from
Little Rock, AR
Click here to add this to my saved trials